RESUMEN
BACKGROUND: The use of preventive measures, including effective chemoprophylaxis, is essential for protection against malaria among travelers. However, data have shown that travelers and medical advisors are confused by the lack of uniform recommendations and numerous prophylactic regimens of varying effectiveness that are used. METHODS: To assess the use and type of preventive measures against malaria, we conducted a cross-sectional study in 1997 among travelers departing from the Nairobi and Mombasa airports in Kenya with European destinations. RESULTS: Seventy-five percent of the travelers studied were residents of Europe and 25% were residents of North America; all stayed less than 1 year, and visited malarious areas. Most travelers, 97.1%, were aware of the risk and 91.3% sought pretravel medical advice. Although 95.4% used chemoprophylaxis and/or antimosquito measures, only 61.7% used both regular chemoprophylaxis and two or more antimosquito measures. Compliance with chemoprophylaxis was lowest amongst those who used a drug with a daily, as opposed to, a weekly dosing schedule, stayed more than 1 month, attributed an adverse health event to the chemoprophylaxis, and were less than 40 years of age. Among US travelers, 94.6% of those taking chemoprophylaxis were taking an effective regimen, that is, mefloquine or doxycycline. Only 1.9% used a suboptimal drug regimen, such as chloroquine/proguanil. Among European travelers, 69% used mefloquine or doxycycline, and 25% used chloroquine/proguanil. Notably, 45.3% of travelers from the UK used chloroquine/proguanil. Adverse events were noted by 19.7% of mefloquine users and 16.4% of travelers taking chloroquine/proguanil. Neuropsychologic adverse events were reported by 7.8% of users of mefloquine and 1.9% of those taking chloroquine/proguanil. The adverse events, however, had a lesser impact on compliance than frequent dosing schedule. CONCLUSIONS: Health information should be targeted to travelers who are likely to use suboptimal chemoprophylaxis or may be noncompliant with prophylaxis. Uniform recommendations for effective chemoprophylaxis with simple dosing schedules are necessary to reduce rates of malaria among travelers to Africa.
Asunto(s)
Antimaláricos/administración & dosificación , Malaria/prevención & control , Cooperación del Paciente/estadística & datos numéricos , Viaje , Adulto , Estudios Transversales , Esquema de Medicación , Europa (Continente) , Femenino , Humanos , Kenia , Masculino , América del Norte , Encuestas y CuestionariosRESUMEN
The evolving patterns of drug resistance in malaria parasites and changes in recommendations for malaria prevention present a challenge to physicians who advise travellers on chemoprophylaxis. Because compliance with personal protection measures is usually low, children should receive appropriate chemoprophylaxis, including breast-fed infants who are not protected through maternal chemoprophylaxis. For travel to areas where chloroquine resistance has not yet been reported (i.e. parts of Central America, the Caribbean and parts of the Middle East), chloroquine alone is sufficient for antimalarial prophylaxis. Mefloquine is the drug of choice for chemoprophylaxis in areas with chloroquine-resistant Plasmodium falciparum, and can be given to infants and young children. The combination of chloroquine and proguanil is well tolerated in children but is much less effective against drug-resistant malaria. Further research is needed to determine the best dosage regimen for antimalarial drugs used for chemoprophylaxis in children.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria Falciparum/prevención & control , Niño , Preescolar , Cloroquina/uso terapéutico , Doxiciclina/uso terapéutico , Humanos , Lactante , Malaria Falciparum/epidemiología , Mefloquina/uso terapéutico , Primaquina/uso terapéuticoAsunto(s)
Antimaláricos/efectos adversos , Malaria Vivax/tratamiento farmacológico , Errores de Medicación , Mefloquina/efectos adversos , Onicomicosis/tratamiento farmacológico , Primaquina/efectos adversos , Anciano , Anciano de 80 o más Años , Antifúngicos/uso terapéutico , Antimaláricos/administración & dosificación , Sobredosis de Droga , Femenino , Humanos , Masculino , Mefloquina/administración & dosificación , Persona de Mediana Edad , Naftalenos/uso terapéutico , Primaquina/administración & dosificación , TerbinafinaRESUMEN
The effectiveness of mefloquine to prevent malaria caused by Plasmodium falciparum is influenced by the sensitivity of the malaria parasites to this drug. Concern has been raised that resistance to mefloquine may develop in sub-Saharan Africa as has been observed in Southeast Asia. Case reports, along with blood smears to confirm the diagnosis and blood samples to determine the mefloquine concentration, were provided on any Peace Corps volunteer serving in sub-Saharan Africa who was diagnosed with malaria. We defined prophylaxis failures probably due to mefloquine resistance as patients with P. falciparum malaria confirmed at the Centers for Disease Control and Prevention, reported compliance with prophylaxis, no ingestion of mefloquine between date of illness onset and date of blood drawing, and a mefloquine level > or = 620 ng/ml in blood drawn within five days of onset of illness. Between January 1, 1991 and September 6, 1996, 44 (31%) of 140 volunteers with confirmed P. falciparum had blood drawn within five days of onset of illness. Twenty-nine (66%) had not fully complied with prophylaxis. Five of 15 prophylaxis failures in four countries had mefloquine levels > or = 620 ng/ml. Failure of mefloquine prophylaxis is primarily due to noncompliance. Evidence of probable resistance to mefloquine among strains of P. falciparum was found in five Peace Corps volunteers in sub-Saharan Africa. Clusters of well-documented prophylaxis failures need to be followed-up by therapeutic in vivo studies to document parasite resistance to mefloquine. Reduced sensitivity to mefloquine does not (yet) appear to be a significant problem in sub-Saharan Africa.
Asunto(s)
Antimaláricos/farmacología , Malaria Falciparum/prevención & control , Mefloquina/farmacología , Plasmodium falciparum/efectos de los fármacos , Adulto , África del Sur del Sahara/epidemiología , Animales , Antimaláricos/sangre , Antimaláricos/uso terapéutico , Estudios de Cohortes , Resistencia a Medicamentos , Femenino , Agencias Gubernamentales , Humanos , Incidencia , Malaria Falciparum/epidemiología , Masculino , Mefloquina/sangre , Mefloquina/uso terapéutico , Estudios Prospectivos , Viaje , Insuficiencia del Tratamiento , Estados Unidos/etnologíaRESUMEN
Individuals from industrialized nations frequently travel to countries with malaria, so health care providers need to be familiar with current recommendations for prevention of malaria. Changes in drug susceptibility of malaria parasites and evolving knowledge of how well drugs are tolerated necessitate periodic review of guidelines for prophylaxis of malaria, especially of chloroquine-resistant Plasmodium falciparum malaria. Mefloquine is the drug of choice for chemoprophylaxis for most travelers, with doxycycline and chloroquine being less effective alternatives. Mefloquine is well tolerated at prophylactic dosages, but anecdotal reports have raised concerns about its adverse effects. Resistance to this drug has emerged in parts of Southeast Asia and may spread to other regions of the world. The major disadvantages of doxycycline are the need for daily dosing, its contraindication for young children and pregnant women, and its adverse effects. Chloroquine is effective for prophylaxis only in Central America, the Caribbean, and parts of the Middle East. Few new drugs will be available in the near future because of reduced funding for antimalarial drug research and development; therefore, the usefulness of currently available drugs needs to be prolonged by rational use. Increased efforts should be made to ensure that alternative drugs will be available for prevention of malaria.
Asunto(s)
Antimaláricos/uso terapéutico , Salud Global , Malaria/prevención & control , Viaje , Animales , Cloroquina/uso terapéutico , Doxiciclina/uso terapéutico , Resistencia a Medicamentos , Guías como Asunto , Humanos , Mefloquina/uso terapéutico , Plasmodium/efectos de los fármacos , Primaquina/uso terapéutico , Proguanil/uso terapéuticoRESUMEN
Because of the widespread presence of chloroquine-resistant Plasmodium falciparum malaria, mefloquine is now the recommended drug of choice for long-term malaria prophylaxis in these areas. Although several studies have compared plasma and whole blood concentrations of either mefloquine or its carboxylic acid metabolite, we report the first comparison of serum and whole blood levels in 86 Dutch marines taking 250 mg of mefloquine weekly for 18 weeks while deployed in western Cambodia. All samples were taken during steady-state and at 42-48 hr after the most recent dose. The concentration of mefloquine in serum (mean = 979 ng/ml) was significantly greater than in whole blood (mean = 788 ng/ml) (P < 0.00001, by paired t-test) with an overall mean ratio of 1.28. The concentration of the metabolite in serum (mean = 3,039 ng/ml) was also significantly greater than in whole blood (mean = 1,390 ng/ml) (P < 0.00001, by paired t-test) with an overall mean ratio of 2.25. These findings are similar to previous reports of plasma-to-whole blood levels. Furthermore, we report that the within-individual ratios of the metabolite concentration to the mefloquine concentration were also found to be significantly different in serum (3.79; P < 0.00001, by paired t-test) and in whole blood (2.02; P < 0.00001, by paired t-test). Appropriate attention must be given to these differences when comparing serum and whole blood concentrations of either mefloquine or its metabolite to avoid misinterpretation of their respective levels. Also, the determination of the relative mefloquine ratios in various blood fluids, as well as the documentation of the metabolite levels and their ratios, is critical to the appropriate interpretation of both chemoprophylaxis and chemotherapy, especially in the presence of resistant strains.
Asunto(s)
Antimaláricos/sangre , Malaria Falciparum/prevención & control , Mefloquina/sangre , Antimaláricos/administración & dosificación , Cambodia , Ácidos Carboxílicos/sangre , Humanos , Mefloquina/administración & dosificación , Personal Militar , Países Bajos/etnologíaRESUMEN
Due to presumed adverse performance impact, a World Health Organization clause currently restricts the use of mefloquine malaria chemoprophylaxis in individuals requiring fine coordination and spatial discrimination. We conducted a double-blind, placebo-controlled, cross-over study to quantitatively assess the effects of mefloquine at steady state on performance in 23 trainee airline pilots. Flying performance was assessed using a flight simulator, psychomotor function was evaluated, sleep and wake cycles were monitored, and symptoms and moods were assessed using standardized questionnaires. A simplified postural sway meter recorded sway in three test positions. In the mefloquine loading dose phase, there was one withdrawal due to dizziness, diarrhea, and flu-like symptoms, and three volunteers reported nonserious, sleep-related adverse events. There was no significant difference in flying performance, psychomotor functions, or mean sway for any test position. Nonsignificant reductions in mean total nocturnal sleep (mefloquine = 450 min versus placebo = 484 min) and poorer sleep quality were detected in the mefloquine phases. The mood findings indicated a predominance of positive states, with vigor the predominant mood in all phases. No significant performance deficit was documented under laboratory conditions during use of mefloquine at steady state.
Asunto(s)
Medicina Aeroespacial , Antimaláricos/efectos adversos , Malaria/prevención & control , Mefloquina/efectos adversos , Desempeño Psicomotor/efectos de los fármacos , Sueño/efectos de los fármacos , Adulto , Afecto/efectos de los fármacos , Antimaláricos/administración & dosificación , Antimaláricos/uso terapéutico , Estudios Cruzados , Diarrea/inducido químicamente , Mareo/inducido químicamente , Método Doble Ciego , Femenino , Humanos , Masculino , Mefloquina/administración & dosificación , Mefloquina/uso terapéutico , Postura , Enfermedades Respiratorias/inducido químicamente , ViajeRESUMEN
This longitudinal study of travellers to Africa taking mefloquine (MQ) chemoprophylaxis aimed to quantify and assess non-serious adverse events (AE) occurring during short-term prophylaxis and relate these to concentrations of racemic MQ, its enantiomers and metabolite. A total of 420 volunteers (52% F) participated. AEs with some impact on activities were reported by 11.2% of participants including 7.9% of neurological/psychiatric symptoms. Women were more likely to report AEs (P = 0.02). The standardized questionnaires used showed more pathological indicators in travellers who reported subjective AE with significantly more dizziness, distress, sleep disturbances and a high total mood disturbance (TMD) in the AE group. There was, however, no significant performance deficit in computerized psychomotor tests in those experiencing AE. Furthermore, no significant differences were observed in enantiomer ratios, metabolite concentrations, or racemic MQ levels in participants with or without AEs suggesting that these factors are not the main predictors of mefloquine intolerability.
Asunto(s)
Malaria Falciparum/prevención & control , Mefloquina/efectos adversos , Adolescente , Adulto , África , Tolerancia a Medicamentos , Femenino , Humanos , Estudios Longitudinales , Masculino , Mefloquina/química , Persona de Mediana Edad , Cooperación del Paciente , Factores Sexuales , Estereoisomerismo , Encuestas y Cuestionarios , ViajeRESUMEN
Three Dutch marine battalions (n=2289) serving in Western Cambodia during 1992-1993 used mefloquine as weekly malaria chemoprophylaxis. One battalion started with a loading dose. Full compliance with prophylaxis was reported by 86.3%, and possible mefloquine-related adverse events were reported by 30.2%. Sixty-four periods of malaria were diagnosed in 59 marines. During deployment, 31 Plasmodium falciparum and no Plasmodium vivax infections occurred. After return, there were 11 cases of falciparum malaria and 22 of vivax malaria, 16-72 days and 30-540 days, respectively, after stopping prophylaxis. Mefloquine-resistant parasites were isolated from 4 Dutch and 4 Khmer patients. Long-term mefloquine prophylaxis was well tolerated but not totally effective.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria Falciparum/prevención & control , Malaria Vivax/prevención & control , Mefloquina/uso terapéutico , Personal Militar , Adolescente , Adulto , Animales , Antimaláricos/efectos adversos , Cambodia , Femenino , Humanos , Masculino , Mefloquina/efectos adversos , Persona de Mediana Edad , Países BajosRESUMEN
PURPOSE: United States military personnel deployed to Somalia were at risk for malaria, including chloroquine-resistant Plasmodium falciparum malaria. This report details laboratory, clinical, preventive, and therapeutic aspects of malaria in this cohort. PATIENTS AND METHODS: The study took place in US military field hospitals in Somalia, with US troops deployed to Somalia between December 1992 and May 1993. Centralized clinical care and country-wide disease surveillance facilitated standardized laboratory diagnosis, clinical records, epidemiologic studies, and assessment of chemoprophylactic efficacy. RESULTS: Forty-eight cases of malaria occurred among US troops while in Somalia; 41 of these cases were P falciparum. Risk factors associated with malaria included: noncompliance with recommended chemoprophylaxis (odds ratio [OR] 2.4); failure to use bed nets (OR 2.6); and failure to keep sleeves rolled down (OR 2.2). Some patients developed malaria in spite of mefloquine (n = 8) or doxycycline (n = 5) levels of compatible with chemoprophylactic compliance. Five mefloquine failures had both serum levels > or = 650 ng/mL and metabolite:mefloquine ratios over 2, indicating chemoprophylactic failure. All cases were successfully treated, including 1 patient who developed cerebral malaria. CONCLUSIONS: P falciparum malaria attack rates were substantial in the first several weeks of Operation Restore Hope. While most cases occurred because of noncompliance with personal protective measures or chemoprophylaxis, both mefloquine and doxycycline chemoprophylactic failures occurred. Military or civilian travelers to East Africa must be scrupulous in their attention to both chemoprophylaxis and personal protection measures.
Asunto(s)
Malaria Falciparum/diagnóstico , Personal Militar , Antibacterianos/sangre , Antibacterianos/uso terapéutico , Antimaláricos/sangre , Antimaláricos/uso terapéutico , Quimioprevención , Cloroquina/uso terapéutico , Vestuario , Estudios de Cohortes , Doxiciclina/sangre , Doxiciclina/uso terapéutico , Resistencia a Medicamentos , Humanos , Malaria Cerebral/diagnóstico , Malaria Cerebral/tratamiento farmacológico , Malaria Falciparum/tratamiento farmacológico , Malaria Falciparum/prevención & control , Masculino , Mefloquina/sangre , Mefloquina/uso terapéutico , Vigilancia de la Población , Estudios Prospectivos , Equipos de Seguridad , Pirimetamina/uso terapéutico , Quinina/uso terapéutico , Factores de Riesgo , Somalia , Sulfadoxina/uso terapéutico , Insuficiencia del Tratamiento , Negativa del Paciente al Tratamiento , Estados UnidosRESUMEN
PROBLEM/CONDITION: Malaria is caused by one of four species of Plasmodium (i.e., P. falciparum, P. vivax, P. ovale, or P. malariae) and is transmitted by the bite of an infective female Anopheles sp. mosquito. Most malaria cases in the United States occur among persons who have traveled to areas that have ongoing transmission. However, cases are transmitted occasionally through exposure to infected blood products, by congenital transmission, or by local mosquito-borne transmission. Malaria surveillance is conducted to identify episodes of local transmission and to guide prevention recommendations. REPORTING PERIOD COVERED: Cases with onset of illness during 1992. DESCRIPTION OF SYSTEM: Malaria cases were identified at the local level (i.e., by healthcare providers or through laboratory-based surveillance). All suspected cases were confirmed by slide diagnosis and then reported to the respective state health department and to CDC. RESULTS: CDC received reports of 910 cases of malaria that had onset of symptoms during 1992 among persons in the United States and its territories. In comparison, 1,046 cases were reported for 1991, representing a decrease of 13% in 1992. P. vivax, P. falciparum, P. malariae, and P. ovale were identified in 51%, 33%, 4%, and 3% of cases, respectively. The species was not identified in the remaining 9% of cases. The number of reported malaria cases that had been acquired in Africa by U.S. civilians decreased 38%, primarily because the number of P. falciparum cases declined. Of U.S. civilians whose illnesses were diagnosed as malaria, 81% had not taken a chemoprophylactic regimen recommended by CDC. Seven patients had acquired their infections in the United States. Seven deaths were attributed to malaria. INTERPRETATION: The decrease in the number of P. falciparum cases in U.S. civilians could have resulted from a change in travel patterns, reporting errors, or increased use of more effective chemoprophylaxis regimens. ACTIONS TAKEN: Additional information was obtained concerning the seven fatal cases and the seven cases acquired in the United States. Malaria prevention guidelines were updated and disseminated to health-care providers. Persons traveling to a malaria-endemic area should take the recommended chemoprophylaxis regimen and use personal protection measures to prevent mosquito bites. Any person who has been to a malarious area and who subsequently develops a fever or influenza-like symptoms should seek medical care, which should include a blood smear for malaria. The disease can be fatal if not diagnosed and treated at an early stage of infection. Recommendations concerning prevention and treatment of malaria can be obtained from CDC.
Asunto(s)
Malaria/epidemiología , Femenino , Humanos , Malaria/diagnóstico , Malaria/prevención & control , Masculino , Vigilancia de la Población , Estados Unidos/epidemiologíaRESUMEN
Background: Although approximately 1000 U.S. citizens per year are reported to the Centers for Disease Control and Prevention as having acquired malaria infection during foreign travel, little information exists with regard to the cost and appropriateness of malaria therapy received in the United States. Methods: Data on treatment of U.S. citizens reported to the Centers for Disease Control and Prevention (CDC) as having acquired Plasmodium falciparum malaria in 1988-1989 while traveling in subSaharan Africa were collected by phone interview. These data were used to derive a relative index of illness severity, to estimate the costs of malaria-specific therapy, and to assess adherence to existing therapy recommendations. All monetary values throughout this study will be expressed in U.S. dollars. Results: Of 142 patients, 110 (77%) were classified as having mild, 21 (15%) as having moderate, and 11 (8%) as having severe infections. Two (1.4%) deaths were reported. Overall, the mean (6 standard deviation) cost of treatment per case was $2743.51 (6 8416.82; range $191.75 to $79,801.73). Estimated with relation to severity, the median cost for treatment per case was $467.54 for mild, $2701.16 for moderate, and $12,515.52 for severe infections. Forty-two (30%) of these patients had at least one element of therapy that was inconsistent with recommendations current at the time of the study; 27(19%) received chloroquine; 12 (9%) received primaquine unnecessarily; eight (6%) received inappropriate dosages of pyrimethamine/sulfadoxine (Fansidar)*; and three (2%) received potentially inappropriate dosing regimens of quinine. Conclusions: The relatively low fatality rate, and the fact that 70% of patients received appropriate therapy suggests that the overall standard of care for what is a relatively infrequent disease in the United States is good. However, because of rapidly changing drug resistance patterns, both physicians and travelers need to remain informed to avoid the costs and risks of this potentially severe, but easily preventable infectious disease. (J Travel Med 2:16-21, 1995)
RESUMEN
OBJECTIVE: To identify malaria in US Marines returning from Somalia and to determine their compliance with chemoprophylaxis. DESIGN: Case series. SETTING: The US Navy health care system. PATIENTS: Consecutive sample of 106 US Marines diagnosed with malaria after returning from Somalia in 1993. MAIN OUTCOME MEASURES: Identification of the incidence and clinical features of imported malaria. Determination of compliance with chemoprophylaxis in this cohort. RESULTS: As of December 20, 1993, there were 112 cases of imported malaria in 106 US Marine Corps personnel returning from Somalia. Plasmodium vivax accounted for 97 (87%) of 112 malaria cases, and Plasmodium falciparum accounted for eight (7%) of 112 cases. Mixed infection with P vivax and P falciparum was noted in six (5%) of 112 cases, and a single case of Plasmodium malariae was identified. Patients with P falciparum malaria were diagnosed a mean of 20.9 days (range, 1 to 82 days) after returning to the United States compared with 91.8 days (range, 7 to 228 days) for P vivax infection (P < .0001). The self-reported chemoprophylaxis compliance rate was 56%; however, only 45 (50%) of 90 patients were given an optimal chemoprophylaxis regimen. CONCLUSIONS: Noncompliance with personal protective measures and chemoprophylaxis contributed to the largest outbreak of imported malaria in US military personnel since the Vietnam conflict. Since military personnel frequently go on leave after deployment, health care providers throughout the United States must be aware of the presence of imported malaria from Somalia.
Asunto(s)
Brotes de Enfermedades , Malaria/epidemiología , Personal Militar , Estudios de Cohortes , Doxiciclina/uso terapéutico , Humanos , Incidencia , Malaria/prevención & control , Mefloquina/uso terapéutico , Personal Militar/estadística & datos numéricos , Primaquina/uso terapéutico , Somalia , Negativa del Paciente al Tratamiento , Estados UnidosRESUMEN
Five Aotus monkeys and two chimpanzees were infected with Plasmodium malariae isolated from a patient who acquired her infection approximately 50 years ago. All animals were splenectomized. The chimpanzees supported the highest parasite densities of 22,271/microliters and 18,544/microliters. Three Aotus monkeys with a previous history of infection with P. vivax had maximum parasite counts of from 1,818/microliters to 2,909/microliters, whereas two monkeys not previously infected had maximum parasite counts of 6,908/microliters. The establishment of new isolates in these animals aides the development of diagnostic probes and the identification of areas of antigenic variation within the species.
Asunto(s)
Aotus trivirgatus/parasitología , Malaria/parasitología , Pan troglodytes/parasitología , Plasmodium malariae/crecimiento & desarrollo , Anciano , Animales , China , Cloroquina/uso terapéutico , Femenino , Humanos , Malaria/sangre , Malaria/tratamiento farmacológico , Malaria/etiología , Masculino , Esplenectomía , Factores de Tiempo , Reacción a la TransfusiónRESUMEN
We have characterized the circumsporozoite (CS) gene sequences of Plasmodium malariae China-1 CDC, isolated recently from a person who was infected 50 years ago in China, and P. vivax Chesson, isolated 48 years ago from a patient who had returned from New Guinea. These protein sequences were compared with the CS protein sequences of recently isolated P. vivax and P. malariae parasites. In a similar manner, we compared the previously characterized CS protein gene of P. falciparum clone 7G8, derived from a Brazilian isolate collected in 1980, with the CS protein genes of recent P. falciparum field isolates. In the case of the P. malariae CS protein gene, with the exception of an additional copy of major (NAAG) and minor (NDAG) repeat sequences and the presence of one copy of NDEG sequence, the China-1 CDC P. malariae parasite is similar to the Uganda-1 CDC isolate of 1982. In the nonrepeat region, changes were noted in two amino acid residues, one of which is also seen in a closely related monkey malaria parasite, P. brasilianum. In the case of P. vivax CS proteins, the nonrepeat region of the protein in Chesson strain shares identity with nearly 71% of the CS clones characterized from field isolates. In the P. falciparum CS proteins, the 7G8 CS protein sequence is identical to 75% of the genes of recent field isolates in the Th1R-N1 region. In the Th2R and Th3R regions, 34% and 55% of the CS clones analyzed, respectively, had changes at two amino acid residues.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Plasmodium malariae/genética , Plasmodium vivax/genética , Polimorfismo Genético , Proteínas Protozoarias/genética , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Brasil , Clonación Molecular , Cartilla de ADN/química , Gambia , Variación Genética , Humanos , Datos de Secuencia Molecular , Papúa Nueva Guinea , Plasmodium malariae/química , Plasmodium vivax/química , Proteínas Protozoarias/química , Secuencias Repetitivas de Ácidos Nucleicos , Estudios RetrospectivosRESUMEN
The spread of chloroquine-resistant Plasmodium falciparum malaria has led to increased use of mefloquine prophylaxis by US Peace Corps volunteers in sub-Saharan Africa. We compared long-term mefloquine with other drug regimens for effectiveness and tolerance. The incidence of Plasmodium falciparum infections and of adverse reactions was compared in Peace Corps volunteers who took chloroquine weekly, mefloquine weekly, mefloquine every other week, or weekly chloroquine plus daily proguanil. Weekly mefloquine was 94% more effective than chloroquine (95% CI 86% to 97%), 86% more effective than chloroquine plus proguanil (95% CI 67% to 94%), and 82% more effective than prophylaxis with mefloquine when taken every other week (95% CI 68% to 90%). No serious adverse reactions were observed. Mild adverse events were equally frequent in mefloquine users and chloroquine users, and the frequency of these events declined with increasing duration of prophylaxis. Mefloquine is an effective and well-tolerated drug for prophylaxis of malaria by short-term and long-term travellers.
Asunto(s)
Malaria Falciparum/prevención & control , Mefloquina/uso terapéutico , África Occidental/epidemiología , Cloroquina/administración & dosificación , Cloroquina/efectos adversos , Cloroquina/uso terapéutico , Estudios de Cohortes , Esquema de Medicación , Quimioterapia Combinada , Humanos , Cuidados a Largo Plazo , Malaria Falciparum/epidemiología , Mefloquina/administración & dosificación , Mefloquina/efectos adversos , Mefloquina/sangre , Proguanil/administración & dosificación , Proguanil/uso terapéuticoRESUMEN
In the United States (US), travelers who have had malaria or who have taken antimalarial chemoprophylaxis are deferred as blood donors for 3 years to prevent transfusion-transmitted malaria. To assess the impact of shortening this 3-year exclusion period, national malaria surveillance data from 1972 to 1988 were reviewed. The average annual rate of transfusion-transmitted malaria is 0.25 cases per million units of blood collected. Of 45 reported cases, 38 percent were caused by Plasmodium malariae, 29 percent by P. falciparum, 24 percent by P. vivax, and 9 percent by P. ovale. Thirty-two donors were implicated in 34 cases of transfusion-transmitted malaria. Of 30 implicated donors whose native country was identified, 23 (77%) were foreign nationals and 7 (23%) were from the US. In a review of all imported malaria cases by species and by interval between date of entry and onset of illness, 98 percent of P. falciparum, 86 percent of P. malariae, 76 percent of P. vivax, and 74 percent of P. ovale infections became symptomatic within 6 months of the patient's arrival in the US, regardless of the use of prophylaxis. Shortening to 6 months the donor exclusion period for US travelers to malarious areas would result in a minimum of 70,000 additional blood donors' being made available, with a maximum annual increase of 0.03 additional cases of transfusion-transmitted malaria. The potential benefit of bringing healthy travelers back into the donor pool after a shorter period of exclusion merits consideration by the blood banking industry.
Asunto(s)
Donantes de Sangre , Malaria/transmisión , Viaje , Adulto , Femenino , Humanos , Incidencia , Malaria/epidemiología , Malaria/prevención & control , Masculino , Persona de Mediana Edad , Reacción a la Transfusión , Estados UnidosRESUMEN
To measure the effectiveness and tolerance of long-term malaria prophylaxis with mefloquine, the incidence of Plasmodium falciparum malaria and of adverse reactions was compared in Peace Corps volunteers in West Africa who took mefloquine every 2 weeks and in volunteers who took chloroquine phosphate weekly. Mefloquine was only 63% more effective than chloroquine; the monthly incidence of P falciparum infections was one case per 100 volunteers who took mefloquine and 2.7 cases per 100 volunteers who took chloroquine. Using daily proguanil (chloroguanide) hydrochloride in addition to chloroquine did not provide additional protection. All mefloquine prophylaxis failures occurred during the second week of the every-2-weeks dosing regimen in volunteers who had used mefloquine for more than 2 months. Blood concentrations of mefloquine were lower during the second week of the alternate-week regimen than during the first week, suggesting that blood levels are too low during the second week to suppress parasitemia. No serious adverse reactions were observed. The results indicate that a dosing regimen of 250 mg of mefloquine weekly should be considered for travelers to areas with chloroquine-resistant P falciparum malaria.